Dr. O'Regan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
601 Elmwood Avenue
Third Floor
Rochester, NY 14642Phone+1 585-486-0600Fax+1 585-486-0649- Is this information wrong?
Education & Training
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1998 - 1999- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 1995 - 1998
Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 1994 - 1995
University College of Dublin National Univ SOMClass of 1988
Certifications & Licensure
WI State Medical License 2015 - 2025
NY State Medical License 2021 - 2024
GA State Medical License 2003 - 2017
IL State Medical License 1995 - 2005- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Atlanta Magazine: Top Doctors Castle Connolly, 2007, 2009-2014
- America's Top Doctors for Cancer Castle Connolly, 2007-2013
Clinical Trials
- Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer Start of enrollment: 2006 Dec 01
- Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores Start of enrollment: 2009 Apr 01
- Phase II Trial of EVEROLIMUS ± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer Start of enrollment: 2009 May 01
- Join now to see all
Publications & Presentations
PubMed
- When the personal becomes political: The impact of the Dobbs decision on women with cancer.Jane Lowe Meisel, Amy Harrington, Natalie Whaley, Wendy Vitek, Ruth M O'Regan> ;Cancer. 2023 Jan 15
- 2 citationsImproving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.David Hicks, Ruth M O'Regan> ;Journal of Clinical Oncology. 2022 Apr 10
- 7 citationsA phase I study of talazoparib (BMN 673) combined with carboplatin and paclitaxel in patients with advanced solid tumors (NCI9782).Ticiana A Leal, Marina N Sharifi, Nancy Chan, Robert Wesolowski, Anita A Turk, Justine Y Bruce, Ruth M O'Regan, Jens Eickhoff, Lisa M Barroilhet, Jyoti Malhotra, Janic...> ;Cancer Medicine. 2022 Nov 1
- Join now to see all
Lectures
- Study TTC-352-101: Phase 1 study of TTC-352 in patients with metastatic breast cancer (BC) progressing on endocrine therapy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
Assay Predicts Breast Cancer Patients Who Will Benefit from Ovarian SuppressionDecember 7th, 2022- New Options for Metastatic HER2-Positive Breast CancerJanuary 18th, 2022
- Using Genomic Profiling to Select the Right Therapy for Metastatic Breast CancerJanuary 11th, 2022
- Join now to see all
Committees
- Vice Chair, NCCN Board of Directors 2019 - Present
- President, Wisconsin Association for Hematology and Oncology 2019 - Present
- Chief Scientific Officer, Big Ten Cancer Research Consortium 2018 - Present
Professional Memberships
- Member
- Member
Hospital Affiliations
Strong Memorial Hospital of the University of RochesterRochester, New York
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
